Latest publications
Finding dose-volume constraints to reduce late rectal toxicity following tridimensional conformal radiotheraphy (3D-CRT) of prostate cancer
Radiother Oncol, 2003, Nov; 69 (2): 215-222. PMID: 1464396
Greco C, Mazzetta C, Catani F, Tossi G, Castiglioni S, Fodor A, Orecchia R.
Meta-analysis of Randomised Trials Comparing Gemcitabine- Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer
Drugs Aging, 2007, 24 (10): 865-879. DOI: 10.2165/00002512-200724100-00006
Banu E, Banu A, Fodor A, Landi B, Rougier Ph, Chatellier G, Andrieu JM, Oudard S, Pompidou G.
Dose escalation for prostate cancer using the three- dimensional conformal dynamic arc techinique: analysis of 542 consecutive patients
Int J Radiat Oncol Biol Phys, 2008, 71 (3): 784-794. doi: 10.1016/j.ijrobp.2007.10.041
Jereczek-Fossa BA, Vavassori A, Fodor C, Santoro L, Zerini D, Cattani F, Garibaldi C, Cambira R, Fodor A, Boboc GI, Vitolo V, Ivaldi GB, Mussi G, De Cobelli O, Orecchia R.
PET- Guided Dose Escalation Tomotherapy in Malignant Pleural Mesothelioma
Strahlenther Onkol 2011, 187 (11): 736-743. doi: 10.1007/s00066-011-2234-6
Fodor A, Fiorino C, Dell’Oca I, Broggi S, Pasetti M, Cattaneo GM, Gianolli L, Calandrino R, Di Muzio NG:
11C-Choline PET/CT as guide to radiation treatment planning of lymph-node relapses in prostate cancer patients
Eur J Nucl Med Mol Imaging 2014, 41(7): 1270-9. doi: 10.1007/s00259-014-2734-6
Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, Fiorino C, Kirienko M, Incerti E, Messa C, Gianolli L, Di Muzio N.
Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single institution analysis of 1176 patients
Eur Urol 2014, 66(6):1024-30. doi: 10.1016/j.eururo.2014.06.012
Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La Macchia M, Noris Chiorda B, Rancoita PM, Suardi N, Zerbetto F, Calandrino R, Montorsi F, Di Muzio N.
Moderate hypofractionation with simultaneous integrated boost in prostate cancer: long-term results of a phase I-II study
Clin Oncol (R Coll Radiol) 2016, 28 (8): 490-500. doi: 10.1016/j.clon.2016.02.005
Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell’Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C.
Toxicity and efficacy of salvage 11C-Choline PET/CT- guided radiation therapy in patients with prostate cancer lymph nodal recurrence
BJU Int 2017, 119 (3): 406-413. 10.1111/bju.13510
Fodor A, Berardi G, Fiorino C, Picchio M, Busnardo E, Kirienko M, Incerti E, Dell’Oca I, Cozzarini C, Mangili P, Pasetti M, Calandrino R, Gianolli L, Di Muzio NG:
Read more
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row
World J Urol 2018;
Fodor A, Lancia A, Ceci F, Picchio M, Hoyer M, Jereczek-Fossa BA, Ost P, Castelucci P, Incerti E, Di Muzio N, Ingrosso G:
Read more
A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy
Eur Urol 2019, doi: 10.1016/j.eururo.2019.07.009
De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van as N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL; Ponti E, Marvaso G, Goetghebeur E, Ost P. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer:
A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study)
A collaboration of MITO, AIRO GYN, and MaNGO Groups. The Oncologist 2019,
Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D’Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F, Scorsetti M; Cilla S, Ingargiola R, Huscher A, Cerrotta AM, Fodor A, Vicenzi L, Russo D, Borghesi S, Perrucci E, Pignata S, Aristei C, Morganti AG, Scambia G, Valentini V, Jereczek-Fossa BA, Ferrandina G.
Read more
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
Breast, 2021 Feb;55:45-54. doi: 10.1016/j.breast.2020.12.004.
A Fodor, C Brombin, P Mangili, F Borroni, M Pasetti, R Tummineri, F Zerbetto, B Longobardi, L Perna, I Dell'Oca, CL Deantoni, AM Deli, A Chiara, S Broggi, R Castriconi, P Esposito, N Slim, P Passoni, S Baroni, SL Villa, PMV Rancoita, C Fiorino, A Del Vecchio, G Bianchini, OD Gentilini, MS Di Serio, NG Di Muzio.
Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer
Cancers (Basel). 2021 Oct 3;13(19):4970. doi: 10.3390/cancers13194970
Di Muzio NG, Deantoni CL, Brombin C, Fiorino C, Cozzarini C, Zerbetto F, Mangili P, Tummineri R, Dell'Oca I, Broggi S, Pasetti M, Chiara A, Rancoita PMV, Del Vecchio A, Di Serio MS, Fodor A.
A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer
The LaIT-SABR study. Radiother Oncol. 2022 Jan;166:92-99. doi: 10.1016/j.radonc.2021.10.023
L Nicosia, D Franceschini, F Perrone-Congedi, F Casamassima, MA Gerardi, M Rigo, R Mazzola, M Perna, V Scotti, A Fodor, A Iurato, F Pasqualetti, G Gadducci, S Chiesa, RM Niespolo, A Bruni, G Alicino, L Frassinelli, P Borghetti, A Di Marzo, A Ravasio, B De Bari, M Sepulcri, D Aiello, G Mortellaro, C Sangalli, M Franceschini, G Montesi, FM Aquilanti, G Lunardi, R Valdagni, I Fazio, G Scarzello, L Corti, V Vavassori, E Maranzano, SM Magrini, S Arcangeli, MA Gambacorta, V Valentini, F Paiar, S Ramella, NG Di Muzio, L Livi, BA Jereczek-Fossa, MF Osti, M Scorsetti, F Alongi.
Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients
Clin Breast Cancer. 2022 Jun;22(4):e480-e487. doi: 10.1016/j.clbc.2021.11.008
Fodor A, Brombin C, Mangili P, Tummineri R, Pasetti M, Zerbetto F, Longobardi B, Galvan AS, Deantoni CL, Dell'Oca I, Castriconi R, Esposito PG, Deli AM, Rancoita PMV, Fiorino C, Vecchio AD, Di Serio MS, Di Muzio NG.
